Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.38 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5102742 | 0.80 | IRAK4 (0.46) | IRAK4ALDH1A1MAPTSMN1; SMN2PAK4 | |
| SCHEMBL5090482 | 0.79 | IRAK4 (0.52) | IRAK4PAK4PIKFYVE | |
| SCHEMBL20357894 | 0.76 | CDC7 (0.57) | KDRCDC7ALDH1A1MAPTMEN1 | |
| SCHEMBL3824181 | 0.76 | MKNK1 (0.48) | CDC7IRAK4ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5102172 | 0.75 | IRAK4 (0.49) | IRAK4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL18414247 | 0.73 | CDC7 (0.44) | KDRCDC7IRAK4ALDH1A1MAPT | |
| SCHEMBL5096332 | 0.73 | ROCK1 (0.42) | KDRIRAK4ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5096146 | 0.72 | MAPK8 (0.67) | KDR | |
| SCHEMBL5096150 | 0.72 | MAPK8 (0.67) | KDR | |
| SCHEMBL476742 | 0.71 | MEN1 (0.51) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399462-B2 | 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain | ROCHE PALO ALTO LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399462-B2 | 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain | ROCHE PALO ALTO LLC (US) | 2013-03-19 | — | — | US | disclosed |
| CN-101547917-A | Substituted pyrimidines and their use as JNK modulators | HOFFMANN LAROCHE (CH) | 2009-09-30 | — | — | CN | disclosed |
| US-20080146565-A1 | JNK modulators | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
| US-20080146565-A1 | JNK modulators | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146565-A1 | JNK modulators | MAPKAPK2, MAPKAPK3, MAP3K10 | KDR 3444/4885CDC7 298/4885IRAK4 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.